💸 Weekly Funding Recap: November 13


📇 Company: Orakl Oncology
🏷️ Sectors: TechBio, Artificial Intelligence, Biotechnology
🔍 Description: Develops an AI-powered platform that predicts how cancer drugs will perform in clinical trials using virtual patient models. Spun out of the Gustave Roussy cancer research institute, the company grows tumor organoids from real patient cells, tests them against drugs, and combines the results with genomic, molecular, and clinical data to train predictive AI models. Its technology helps pharmaceutical companies identify promising drug candidates, select patient populations, and reduce clinical development risks.
💻 Website: https://www.orakl-oncology.com/
📍 HQ City: Villejuif
🧗 Round: Series A
💰 Amount Raised: €30 million
🏦 Investors: Norrsken VC, Singular, InfraVia Capital Partners, Serena, Teampact Ventures, Bpifrance, Plug and Play, Verve Ventures, Speedinvest, HCVC. Norrsken
👨💼👩💼 Founders: Fanny Jaulin, Gustave Ronteix, Diane-Laure Pagès
🗞️ News: November 12, 2026. French TechBio startup Orakl Oncology raised $34M in a Series A co-led by Norrsken VC and Singular to expand its AI platform for predicting cancer drug efficacy before clinical trials. The company combines laboratory-grown tumor organoids derived from real patients with molecular and clinical data to create virtual patient cohorts that can be used to test experimental treatments. Orakl claims its technology achieved 90% accuracy in retrospectively predicting outcomes across 40 published oncology clinical trials, although the result has not been independently established. The financing will support a fivefold expansion in data generation, development of models for lung and gastric cancers alongside its existing colorectal and pancreatic cancer work, and the establishment of teams in the United States and United Kingdom. The company also aims to deploy its predictive technology across more than 10 drug-development programs and expand its capabilities for identifying new therapeutic targets. | Sifted, Norrsken VC
To access the full list of deals, become a paid subscriber. Your subscription also unlocks the French Tech Journal’s Live Funding Tracker.